Morphosys AG (MOR) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Morphosys AG (ETR:MOR) have earned a consensus recommendation of “Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is €82.38 ($98.07).
A number of equities analysts have recently weighed in on MOR shares. Berenberg Bank set a €85.00 ($101.19) price target on shares of Morphosys and gave the stock a “buy” rating in a research note on Thursday, December 7th. Commerzbank set a €76.00 ($90.48) price target on shares of Morphosys and gave the stock a “buy” rating in a research note on Tuesday, November 7th. J P Morgan Chase & Co reaffirmed a “buy” rating and issued a price target on shares of Morphosys in a research note on Thursday, November 2nd. Goldman Sachs Group set a €55.00 ($65.48) price target on shares of Morphosys and gave the stock a “neutral” rating in a research note on Tuesday, September 19th. Finally, Deutsche Bank set a €90.00 ($107.14) price target on shares of Morphosys and gave the stock a “buy” rating in a research note on Monday, October 30th.
Shares of Morphosys (ETR:MOR) opened at €76.40 ($90.95) on Thursday. Morphosys has a 1-year low of €43.88 ($52.24) and a 1-year high of €83.83 ($99.80).
Morphosys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Stock Ratings for Morphosys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphosys and related stocks with our FREE daily email newsletter.